Welcome to our dedicated page for Telomir Pharms SEC filings (Ticker: TELO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, offering a structured view of how this preclinical-stage biotechnology company reports its progress and corporate events. Telomir’s filings show that it is a Florida corporation with common stock listed on The Nasdaq Stock Market LLC under the symbol TELO, and they document its focus on developing Telomir-1, a small-molecule therapy targeting epigenetic and metabolic mechanisms in cancer and age-related disease.
For Telomir, Form 8‑K current reports are especially informative. Recent 8‑Ks include Item 8.01 disclosures of new preclinical data, such as Telomir-1’s effects on PSA levels in prostate cancer cells, tumor growth and metastasis in triple-negative breast cancer models, cytotoxicity in leukemia cells, and reductions in intracellular iron compared with the iron chelator Deferoxamine. Another 8‑K details completion of GLP toxicology and safety pharmacology studies in rat and dog models, noting that Telomir-1 was generally well tolerated with no treatment-related adverse or dose-limiting toxicities observed.
Filings also cover corporate and governance matters. Examples include an 8‑K describing a director resignation, compensation committee actions regarding the chief executive officer’s incentives, and a Nasdaq notice related to the timing of the company’s annual shareholder meeting under Listing Rule 5620(a). An additional 8‑K outlines a binding Letter of Intent to acquire TELI Pharmaceuticals, Inc., intended to consolidate worldwide intellectual property and development rights to Telomir-1 within a single public company structure.
On Stock Titan, these filings are supplemented by AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the implications of GLP safety data, oncology study updates, compensation decisions, and Nasdaq communications. Users can review real-time updates from EDGAR, examine narrative descriptions of Telomir-1’s preclinical profile, and track how Telomir reports its IND-enabling activities and strategic transactions over time.
Telomir Pharmaceuticals, Inc. reported that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for Telomir‑Zn, the company’s lead product candidate, to treat advanced or metastatic triple‑negative breast cancer.
The company plans a first‑in‑human Phase 1/2 trial starting in the first half of 2026, enrolling about 76 patients. Phase 1 will focus on safety, tolerability, dose‑limiting toxicities, pharmacokinetics, pharmacodynamics, and early antitumor activity to determine the recommended Phase 2 dose. Phase 2 will assess preliminary efficacy, with objective response rate as the primary endpoint and duration of response, progression‑free survival, overall survival, and safety as key secondary endpoints.
The trial will feature an extensive translational biomarker program to study epigenetic regulation, gene expression, histone modification, and telomere‑related biology, aiming to link target engagement and biomarker changes with clinical outcomes in triple‑negative breast cancer.
Telomir Pharmaceuticals CEO and Chairman Erez Aminov reported a restructuring-related share exchange rather than an open-market trade. He is shown with 7,319,710 shares of common stock at a reported value of $1.3700 per share following the transaction. A footnote explains these Telomir shares were issued to him in exchange for his shares of TELI Pharmaceuticals, Inc. in connection with Telomir’s acquisition of TELI, so the filing reflects how his prior TELI ownership converted into Telomir equity.
Telomir Pharmaceuticals completed its acquisition of TELI Pharmaceuticals, issuing 34,389,710 restricted shares of common stock to TELI’s former shareholders. The share count was based on an exchange ratio derived from independent third-party valuations of both companies.
At closing, Bayshore Trust contributed $1 million to Telomir and entered into an option to pay up to $4 million more for Telomir shares if milestones are met, including FDA acceptance of an Investigational New Drug application and initiation of a Phase 1/2 study for Telomir-1. The deal consolidates all global rights to Telomir-1 under Telomir, giving it full control over development and potential commercialization across major international markets.
Telomir Pharmaceuticals, Inc. reported that on March 30, 2026 it received a letter from the Nasdaq Capital Markets confirming the company is now in compliance with Nasdaq Listing Rule 5620(a) after holding its 2025 Annual Meeting of Shareholders. Nasdaq has determined the matter is closed, meaning Telomir’s listing status related to this meeting requirement is no longer in question.
Telomir Pharmaceuticals, Inc. submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for its lead candidate Telomir-1 (Telomir-Zn) to treat advanced and metastatic triple-negative breast cancer (TNBC). If the IND is cleared, the company plans a Phase 1/2 trial of Telomir-1 as an oral monotherapy.
The Phase 1 portion is expected to use a standard 3+3 dose-escalation design to assess safety, tolerability, dose-limiting toxicities, and select a recommended Phase 2 dose. Phase 2 is expected to use a Simon two-stage design focused on objective response rate as the primary endpoint.
Telomir-1 is described as a first-in-class metal-modulating epigenetic therapy designed to reduce redox-active iron and increase zinc availability, inhibiting iron-dependent epigenetic enzymes such as histone demethylases. The company reports preclinical data showing reduced tumor growth and metastasis in TNBC models, iron-dependent tumor cell death in several human TNBC cell lines, and GLP safety studies with no treatment-related adverse or dose-limiting toxicities observed.
Telomir Pharmaceuticals reported that shareholders approved several major items at the Annual Meeting held on March 23, 2026. They authorized issuing shares of common stock and other securities for the acquisition of Teli Pharmaceuticals that will exceed 20% of the company’s pre-transaction common shares. Shareholders also amended the 2023 Omnibus Incentive Plan, lifting the share reserve from 6,500,000 to 11,500,000 and permitting repricing of options and stock appreciation rights at the plan administrator’s discretion. In addition, the bylaws were amended to reduce the quorum requirement for shareholder meetings to one-third of eligible shares, all director nominees were elected, and the auditor ratification and other compensation-related proposals passed.
Telomir Pharmaceuticals, Inc. files its annual report for the year ended December 31, 2025, describing a preclinical-stage biotech focused on Telomir-1, a small molecule targeting metal-ion dysregulation, oxidative stress, epigenetics, mitochondrial function, and telomere integrity to address aging and age-related diseases.
The company has no revenues, an accumulated deficit of $41.0 million as of December 31, 2025, and its auditors raise substantial doubt about its ability to continue as a going concern. Telomir plans to submit an IND for Telomir-1 in 2026 and then start a Phase 1/2 trial, subject to regulatory and funding constraints.
Telomir relies on a related-party license from MIRALOGX for U.S. rights to Telomir-1, paying an 8% royalty on net sales and certain milestone revenue, while foreign rights remain with MIRALOGX. A pending merger with TELI Pharmaceuticals, Inc. is expected to align worldwide Telomir-1 rights under one public company, with TELI shareholders receiving one Telomir share per TELI share.
Telomir Pharmaceuticals, Inc. is asking its stockholders to approve a merger with TELI Pharmaceuticals, Inc., with a virtual annual meeting scheduled for March 23, 2026. The Merger would issue TELO common stock as consideration based on an Exchange Ratio derived from valuations prepared by Moore.
The Exchange Ratio is based on a $126.8 million valuation for TELI and a $101.1 million valuation for TELO, and the parties expect pre‑Merger holders of each company to own approximately 50% of the combined company immediately after closing. Shares of TELO Common Stock outstanding as of the record date were 34,380,971 as of January 23, 2026. Proposal No. 1 (the Merger Proposal) is a condition to closing.
Telomir Pharmaceuticals, Inc. reported new preclinical in vitro results for its investigational compound Telomir-1 (Telomir-Zn) in human triple-negative breast cancer (TNBC) cell lines. Telomir-Zn showed near-complete tumor cell mortality at 72 hours in the MDA-MB-468 model and significant partial reductions in viable tumor cells in the HCC70 and MDA-MB-231 models.
The company also found that adding supplemental iron reduced Telomir-Zn–induced tumor cell mortality, which it interprets as supporting an iron-dependent mechanism consistent with previously disclosed intracellular metal-modulating activity. Additional TNBC lines (BT-549 and HCC1806) are under evaluation, and a TNBC mouse xenograft study is being prepared in a mammalian system.
Telomir referenced earlier zebrafish xenograft work where Telomir-Zn achieved statistically significant reductions in tumor growth and metastasis in select TNBC models. It reiterated that it is continuing IND-enabling activities and anticipates submitting an Investigational New Drug application in the first quarter of 2026, after previously completing GLP safety and toxicology studies in rats and dogs without treatment-related adverse toxicity.
Telomir Pharmaceuticals, Inc. shareholder John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust and in his individual capacity, reports beneficial ownership of 3,245,000 shares of common stock, representing 9.438% of the class. He has sole power to vote and dispose of all these shares, with no shared voting or dispositive power. The filing states that the securities were not acquired and are not held for the purpose of changing or influencing control of Telomir, indicating a passive investment intent under the Schedule 13G framework.